A former MedImmune president and seasoned local biotech CEO, Peter Greenleaf, has been tapped to head a Canadian pharmaceutical firm. Greenleaf is the new CEO of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies commercializing therapies to treat patient populations that are impacted by serious diseases with a high unmet medical need. The public traded British Columbia company reported revenue of $463,000…
from https://www.bizjournals.com/baltimore/news/2019/04/22/former-medimmune-president-greenleaftapped-to-lead.html?ana=RSS&s=article_search
via https://baltimorecheckbook.tumblr.com/post/184371532262
No comments:
Post a Comment